BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 29641561)

  • 1. Discovery of genetic variants of the kinases that activate tenofovir among individuals in the United States, Thailand, and South Africa: HPTN067.
    Figueroa DB; Tillotson J; Li M; Piwowar-Manning E; Hendrix CW; Holtz TH; Bokoch K; Bekker LG; van Griensven F; Mannheimer S; Hughes JP; Grant RM; Bumpus NN
    PLoS One; 2018; 13(4):e0195764. PubMed ID: 29641561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of Genetic Variants of the Kinases That Activate Tenofovir in a Compartment-specific Manner.
    Lade JM; To EE; Hendrix CW; Bumpus NN
    EBioMedicine; 2015 Sep; 2(9):1145-52. PubMed ID: 26501112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Naturally Occurring Mutations to Muscle-Type Creatine Kinase Impact Its Canonical and Pharmacological Activities in a Substrate-Dependent Manner In Vitro.
    Mosher EP; Eberhard CD; Bumpus NN
    Mol Pharmacol; 2021 Dec; 100(6):588-596. PubMed ID: 34561299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic Variation of the Kinases That Phosphorylate Tenofovir and Emtricitabine in Peripheral Blood Mononuclear Cells.
    Figueroa DB; Madeen EP; Tillotson J; Richardson P; Cottle L; McCauley M; Landovitz RJ; Andrade A; Hendrix CW; Mayer KH; Wilkin T; Gulick RM; Bumpus NN
    AIDS Res Hum Retroviruses; 2018 May; 34(5):421-429. PubMed ID: 29455571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High resistance barrier to tenofovir alafenamide is driven by higher loading of tenofovir diphosphate into target cells compared to tenofovir disoproxil fumarate.
    Margot NA; Liu Y; Miller MD; Callebaut C
    Antiviral Res; 2016 Aug; 132():50-8. PubMed ID: 27208653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tenofovir disoproxil fumarate: a nucleotide reverse transcriptase inhibitor for the treatment of HIV infection.
    Fung HB; Stone EA; Piacenti FJ
    Clin Ther; 2002 Oct; 24(10):1515-48. PubMed ID: 12462284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression, Activity, and Regulation of Phosphorylating Enzymes in Tissues and Cells Relevant to HIV-1 Sexual Transmission.
    Hu M; Valicherla GR; Zhou T; Hillier SL; Rohan LC
    AIDS Res Hum Retroviruses; 2022 Jan; 38(1):22-32. PubMed ID: 33567990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High prevalence of the K65R mutation in HIV-1 subtype C infected patients failing tenofovir-based first-line regimens in South Africa.
    Skhosana L; Steegen K; Bronze M; Lukhwareni A; Letsoalo E; Papathanasopoulos MA; Carmona SC; Stevens WS
    PLoS One; 2015; 10(2):e0118145. PubMed ID: 25659108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tenofovir alafenamide (TAF) does not deplete mitochondrial DNA in human T-cell lines at intracellular concentrations exceeding clinically relevant drug exposures.
    Stray KM; Park Y; Babusis D; Callebaut C; Cihlar T; Ray AS; Perron M
    Antiviral Res; 2017 Apr; 140():116-120. PubMed ID: 28131805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population Pharmacokinetic Modeling of Tenofovir in the Genital Tract of Male HIV-Infected Patients.
    Valade E; Bouazza N; Lui G; Illamola SM; Benaboud S; Treluyer JM; Cobat A; Foissac F; De Sousa Mendes M; Chenevier-Gobeaux C; Suzan-Monti M; Rouzioux C; Assoumou L; Viard JP; Urien S; Ghosn J; Hirt D
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 27956420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment. Tenofovir-resistant HIV increasing in Africa.
    AIDS Policy Law; 2016 Mar; 31(4):1. PubMed ID: 27372984
    [No Abstract]   [Full Text] [Related]  

  • 12. Mutations in muscle-type creatine kinase impact HIV prevention.
    Migliorati JM; Zhong XB
    Trends Pharmacol Sci; 2022 Mar; 43(3):165-167. PubMed ID: 34887127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment options after virological failure of first-line tenofovir-based regimens in South Africa: an analysis by deep sequencing.
    Casadellà M; Noguera-Julian M; Sunpath H; Gordon M; Rodriguez C; Parera M; Kuritzkes DR; Marconi VC; Paredes R
    AIDS; 2016 Apr; 30(7):1137-40. PubMed ID: 26807968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential Mechanisms of Tenofovir and Tenofovir Disoproxil Fumarate Cellular Transport and Implications for Topical Preexposure Prophylaxis.
    Taneva E; Crooker K; Park SH; Su JT; Ott A; Cheshenko N; Szleifer I; Kiser PF; Frank B; Mesquita PM; Herold BC
    Antimicrob Agents Chemother; 2015 Dec; 60(3):1667-75. PubMed ID: 26711762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brief Report: Selection of HIV-1 Variants With Higher Transmission Potential by 1% Tenofovir Gel Microbicide.
    Ngandu NK; Carlson JM; Chopera DR; Ndabambi N; Abdool Karim Q; Abdool Karim S; Williamson C
    J Acquir Immune Defic Syndr; 2017 Sep; 76(1):43-47. PubMed ID: 28797020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV-1 Protease, Reverse Transcriptase, and Integrase Variation.
    Rhee SY; Sankaran K; Varghese V; Winters MA; Hurt CB; Eron JJ; Parkin N; Holmes SP; Holodniy M; Shafer RW
    J Virol; 2016 Jul; 90(13):6058-6070. PubMed ID: 27099321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of low-level HIV-1 variants with reverse transcriptase mutation K65R and the effect of antiretroviral drug exposure on variant levels.
    Kozal MJ; Chiarella J; St John EP; Moreno EA; Simen BB; Arnold TE; Lataillade M
    Antivir Ther; 2011; 16(6):925-9. PubMed ID: 21900725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selectivity of kinases on the activation of tenofovir, an anti-HIV agent.
    Varga A; Gráczer E; Chaloin L; Liliom K; Závodszky P; Lionne C; Vas M
    Eur J Pharm Sci; 2013 Jan; 48(1-2):307-15. PubMed ID: 23201309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic variation of kinases and activation of nucleotide analog reverse transcriptase inhibitor tenofovir.
    Hamlin AN; Tillotson J; Bumpus NN
    Pharmacogenomics; 2019 Jan; 20(2):105-111. PubMed ID: 30628547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypomorphic variants in AK2 reveal the contribution of mitochondrial function to B-cell activation.
    Chou J; Alazami AM; Jaber F; Hoyos-Bachiloglu R; Jones J; Weeks S; Alosaimi MF; Bainter W; Cangemi B; Badran YR; Mohammed R; Alroqi F; Almutairi A; Al-Onazi N; AlAjaji S; Al-Saud B; Arnaout R; Elkins M; Devana S; Imperial J; Li B; Drexhage L; Abdel Rahman AM; Jacob M; Haddad H; Hanna-Wakim R; Dbaibo G; Massaad MJ; Dasouki M; Mikhael R; Baz Z; Geha RS; Al-Mousa H
    J Allergy Clin Immunol; 2020 Jul; 146(1):192-202. PubMed ID: 31862378
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.